Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3060% above fair value
$69.31+0.34 (+0.49%)
Close on Nov 13, 2026Market cap $39.85BP/E 48.8Yield –
Royalty Pharma EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Royalty Pharma's EV/EBITDA was 33.2× on Nov 11, 2026, against 22.3× a year earlier. Over the last 5 years it ranged from 15.3× to 81.7×, with a median of 26.3×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 33.2× | +11.4 |
| 2025 | Dec 31, 2025 | 21.7× | +5.4 |
| 2024 | Dec 31, 2024 | 16.3× | −45.4 |
| 2023 | Dec 29, 2023 | 61.7× | +27.6 |
| 2022 | Dec 30, 2022 | 34.2× | +14.1 |
| 2021 | Dec 31, 2021 | 20.1× | – |
See a number that looks wrong?